Table 1.
Patient characteristics.
| Patient characteristics | CT + B (N = 64) No. (%) | CT (N = 65) No. (%) |
|---|---|---|
| Median age, years (range) | 69 (34–83) | 67 (33–82) |
| Gender | ||
| Male | 40 (62.5) | 35 (53.8) |
| Female | 24 (37.5) | 30 (46.2) |
| Performance Status (ECOG) | ||
| 0 | 54 (84.4) | 53 (81.5) |
| 1−2 | 10 (15.6) | 12 (18.5) |
| Tumor localization | ||
| Rectum | 20 (31.2) | 19 (29.2) |
| Colon | 44 (68.8) | 46 (70.8) |
| Right side | 26# (41%) | 24# (38%) |
| Left side | 37# (59%) | 39# (62%) |
| Stage at diagnosis | ||
| I–III | 14 (21.9) | 15 (23.1) |
| IV | 50 (78.1) | 50 (76.9) |
| Grade | ||
| 1 + 2 | 32 (59.3) | 34 (60.7) |
| 3 | 22 (40.7) | 22 (39.3) |
| Unknown/missing | 10 | 9 |
| CT regimen | ||
| FOLFOX4 | 39 (60.9) | 38 (58.5) |
| FOLFIRI | 25 (39.1) | 27 (41.5) |
| KRAS status* | ||
| Wild type | 37 (59.7) | 36 (60.0) |
| Mutated | 25 (40.3) | 24 (40.0) |
| Unknown/missing | 2 | 5 |
| Prior cancer therapy | ||
| Surgery | 51 (79.7) | 48 (73.8) |
| Radiotherapy | 6 (9.4) | 6 (9.2) |
| Adjuvant chemotherapy | 10 (15.6) | 9 (13.8) |
CT, chemotherapy; B, bevacizumab.
*Required by amendment no. 1 of 3rd May 2009; #Information about which side of the colon was involved was not available for one patient in the CT + B group and 2 patients in the CT group.